Searching for a cure, Improving lives

Clarity required from the Prime Minister over Translarna

Posted on: September 8th, 2015 | 0 comments

Action Duchenne have written to Prime Minister, David Cameron, requesting clarity over his correspondence with Luca Fernandes, who lives with Duchenne muscular dystrophy.

 

On June 9, Action Duchenne and MDUK submitted letters to Number 10 Downing St appealing for an intervention on Translarna. Nevertheless, despite first hand accounts from patients and families detailing the intransigence of NHS England, the life changing benefits of Translarna, and the gross injustice to which they’d been submitted, Mr Cameron refused to intervene, stating that, “decisions about whether the NHS should fund new treatments and drugs for rare diseases are very complex […] and they are rightly made by clinical experts at NHS England, not politicians”.

However, in addition to this comprehensive reply, the Prime Minister also responded to hand written letters from six boys, living with Duchenne. One of these, sent to Luca Fernandes, contains a disquieting statement in which Mr Cameron affirms, “the NHS should not use Translarna until further information becomes available on how well the drug works”.

 

We are concerned that this advice seems to contradict the expectations of the Duchenne community about the scope and considerations of NICE’s ongoing Highly Specialised Technology appraisal of Translarna, which is set to render a funding decision independent of any ‘further information’ on November 17.

Subsequently, we have requested further clarification that the Prime Minister’s statement is not prescient of an impending and premeditated refusal, by NICE, to grant funding approval for Translarna.

 

To read our full letter, click the following link: PM David Cameron Letter

 

Action Duchenne are also investigating the use of Pharmaceutical Price Regulation Scheme (PPRS) payments by NHS England  and the implications that the direction of these resources had upon Translarna’s negative funding decision in July.

 

For more information on the ongoing campaign for access to Translarna, and the broader campaigns work of Action Duchenne, please contact Aaron Revel (Campaigns Officer) on 020 8556 9955 or via aaron@actionduchenne.org

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Summit presents data from Phase 1 clinical programme of lead utrophin modulator, ezutromid

June 22nd, 2017

Summit Therapeutics has today announced the presentation of clinical data from two Phase 1 clinical trials

Tell me more

What Raxone being given approval through the EAMS scheme means for the Duchenne community

June 22nd, 2017

  Over a number of years we have worked closely with Santhera Pharmaceuticals and other

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne